These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12969324)

  • 1. Is macrophage migration inhibitory factor a therapeutic target in systemic lupus erythematosus?
    Hoi AY; Morand EF; Leech M
    Immunol Cell Biol; 2003 Oct; 81(5):367-73. PubMed ID: 12969324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis.
    Santos LL; Morand EF
    Clin Chim Acta; 2009 Jan; 399(1-2):1-7. PubMed ID: 18838066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrophage migration inhibitory factor (MIF) as a therapeutic target for rheumatoid arthritis and systemic lupus erythematosus.
    Bilsborrow JB; Doherty E; Tilstam PV; Bucala R
    Expert Opin Ther Targets; 2019 Sep; 23(9):733-744. PubMed ID: 31414920
    [No Abstract]   [Full Text] [Related]  

  • 4. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
    Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
    Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases.
    Hoi AY; Iskander MN; Morand EF
    Inflamm Allergy Drug Targets; 2007 Sep; 6(3):183-90. PubMed ID: 17897055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic target in inflammatory disease: macrophage migration inhibitory factor.
    Morand EF
    Intern Med J; 2005 Jul; 35(7):419-26. PubMed ID: 15958113
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of disease: macrophage migration inhibitory factor in SLE, RA and atherosclerosis.
    Ayoub S; Hickey MJ; Morand EF
    Nat Clin Pract Rheumatol; 2008 Feb; 4(2):98-105. PubMed ID: 18235539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus.
    Wang FF; Zhu LA; Zou YQ; Zheng H; Wilson A; Yang CD; Shen N; Wallace DJ; Weisman MH; Chen SL; Lu LJ
    Arthritis Res Ther; 2012 May; 14(3):R103. PubMed ID: 22551315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The immunological basis of B-cell therapy in systemic lupus erythematosus.
    Mok MY
    Int J Rheum Dis; 2010 Feb; 13(1):3-11. PubMed ID: 20374380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid-induced leucine zipper (GILZ) inhibits B cell activation in systemic lupus erythematosus.
    Jones SA; Toh AE; Odobasic D; Oudin MA; Cheng Q; Lee JP; White SJ; Russ BE; Infantino S; Light A; Tarlinton DM; Harris J; Morand EF
    Ann Rheum Dis; 2016 Apr; 75(4):739-47. PubMed ID: 26612340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus.
    Mihaylova N; Bradyanova S; Chipinski P; Herbáth M; Chausheva S; Kyurkchiev D; Prechl J; Tchorbanov AI
    Autoimmunity; 2017 Jun; 50(4):257-268. PubMed ID: 28300427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T follicular helper (Tfh) cells in lupus: Activation and involvement in SLE pathogenesis.
    Blanco P; Ueno H; Schmitt N
    Eur J Immunol; 2016 Feb; 46(2):281-90. PubMed ID: 26614103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.
    Moulton VR; Suarez-Fueyo A; Meidan E; Li H; Mizui M; Tsokos GC
    Trends Mol Med; 2017 Jul; 23(7):615-635. PubMed ID: 28623084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Macrophage migration inhibitory factor in systemic lupus erythematosus.
    Foote A; Briganti EM; Kipen Y; Santos L; Leech M; Morand EF
    J Rheumatol; 2004 Feb; 31(2):268-73. PubMed ID: 14760795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current developments of macrophage migration inhibitory factor (MIF) inhibitors.
    Xu L; Li Y; Sun H; Zhen X; Qiao C; Tian S; Hou T
    Drug Discov Today; 2013 Jun; 18(11-12):592-600. PubMed ID: 23466524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrophage migration inhibitory factor and glucocorticoid sensitivity.
    Aeberli D; Leech M; Morand EF
    Rheumatology (Oxford); 2006 Aug; 45(8):937-43. PubMed ID: 16705047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity.
    Bucala R
    J Clin Immunol; 2013 Jan; 33 Suppl 1(Suppl 1):S72-8. PubMed ID: 22968741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The expression of migration inhibitory factor in peripheral blood mononuclear cell and its correlation with disease activity in systemic lupus erythematosus].
    Chen WY; Li GR; Fang F; Yang X; He XS; Zhou FY; Yu XQ
    Zhonghua Nei Ke Za Zhi; 2004 Aug; 43(8):572-5. PubMed ID: 15355659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis.
    Santos LL; Morand EF
    Wien Med Wochenschr; 2006 Jan; 156(1-2):11-8. PubMed ID: 16465610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant B cell selection and activation in systemic lupus erythematosus.
    Kil LP; Hendriks RW
    Int Rev Immunol; 2013 Aug; 32(4):445-70. PubMed ID: 23768157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.